Susan Hasty, Publisher
Table of Contents . . . November 30th, 1998Non-Subscriber - Summaries Only
Conference Coverage (AASLD) - Ribavirin/IFN Therapy Twice as Effective as IFN Alone
Animal Models (HCV) - Mouse Model for HCV Examined
Conference Coverage (AASLD) - HBV Outbreak Linked to Alternative Therapy Reported
Conference Coverage (AASLD) - Roche Seeks FDA Approval for HCV Detecting PCR
Conference Coverage (AASLD) - Small Dose of HEV Results in Subclinical Infection
Conference Coverage (AASLD) - Studies Show Adefovir Efficacy Against HBV
Genomics/Transmission - Swine HEV May Infect Humans
Blood Safety (Transfusions) - Transfusion Recipients Encouraged To Seek Free Blood Tests
Epidemiology - HCV Treatments Predicted Too Late for Many
Industry News (HBV Therapy) - Expanded Access IND Filed for Hepatitis B Drug
Industry News (HBV Therapy) - Phase III Trials for Oral Treatment of HBV, Herpesviruses Announced
Plasma Donation - American Red Cross Opens High-Tech Plasma Center
Drug Development (HCMV) - "RPR CMV423 Inhibits Replication of HCMV at an Early Step of the Virus Replicative Cycle."
HCV/HGV Coinfection - "HGV/GBV-C in Liver Tissue and in Sera from Patients with Chronic Hepatitis C."
Therapy (HCV) - "Incidence of Electrocardiographic Abnormalities During Treatment with Human Leukocyte Interferon-alfa in Patients with Chronic Hepatitis C But Without Preexisting Cardiovascular Disease."
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.